11/12
11:02 am
ovid
Ovid Therapeutics (OVID) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]
High
Report
Ovid Therapeutics (OVID) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]
11/12
08:00 am
ovid
Ovid Therapeutics Reports Business Updates and Third Quarter 2024 Financial Results
Medium
Report
Ovid Therapeutics Reports Business Updates and Third Quarter 2024 Financial Results
10/31
08:00 am
ovid
Ovid Therapeutics to Host Investor Event
Low
Report
Ovid Therapeutics to Host Investor Event
9/30
12:18 pm
ovid
Will Ovid Therapeutics (NASDAQ:OVID) Spend Its Cash Wisely? [Yahoo! Finance]
Low
Report
Will Ovid Therapeutics (NASDAQ:OVID) Spend Its Cash Wisely? [Yahoo! Finance]
9/30
08:01 am
ovid
Ovid Therapeutics Inc. (NASDAQ: OVID) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
Low
Report
Ovid Therapeutics Inc. (NASDAQ: OVID) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
9/27
04:23 am
ovid
Angelman Syndrome (AS) Market Assessment 2024: US and EU5 Epidemiology, Treatment Landscape, Unmet Needs, Emerging Therapies, and Value & Access [Yahoo! Finance]
Medium
Report
Angelman Syndrome (AS) Market Assessment 2024: US and EU5 Epidemiology, Treatment Landscape, Unmet Needs, Emerging Therapies, and Value & Access [Yahoo! Finance]
9/26
08:00 am
ovid
Ovid Therapeutics Presents Pre-Clinical Study Results Demonstrating OV329 Does Not Accumulate in Animal Eyes in Contrast with Vigabatrin
Neutral
Report
Ovid Therapeutics Presents Pre-Clinical Study Results Demonstrating OV329 Does Not Accumulate in Animal Eyes in Contrast with Vigabatrin
9/11
08:00 am
ovid
Meg Alexander Takes on Expanded Role as President and COO at Ovid Therapeutics, Strengthening Leadership for Future Growth
Medium
Report
Meg Alexander Takes on Expanded Role as President and COO at Ovid Therapeutics, Strengthening Leadership for Future Growth
9/6
07:00 am
ovid
Ovid Therapeutics Inc. (NASDAQ: OVID) was upgraded by analysts at William Blair to a "strong-buy" rating.
High
Report
Ovid Therapeutics Inc. (NASDAQ: OVID) was upgraded by analysts at William Blair to a "strong-buy" rating.
9/4
08:00 am
ovid
Ovid Therapeutics to Present at Upcoming September Investor Conferences
Medium
Report
Ovid Therapeutics to Present at Upcoming September Investor Conferences